Cybin Inc (CYBN) Renews $35M At-The-Market Equity Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023 9:37 PM EDTTORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) (Cybin or the Company), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the ATM Program) that allows Cybin to issue and sell up to US$35,000,000 of common shares (Shares) in the capital of the Company from treasury to the public, from time to time, through the Agents (as defined below). All Shares sold under the... More
